PT-141: Research Applications

Research Applications

Published investigations involving bremelanotide fall into the following areas of laboratory and clinical research. These describe the subject matter of the published record and are not statements of effect.

1. Melanocortin receptor pharmacology — Molinoff et al. published the original characterization of the compound as a melanocortin agonist, and Yuan and Tao reviewed the broader ligand landscape for these receptors.[1][5]
2. MC4R structural biology — Zhang et al. resolved ligand recognition and activation mechanisms at the melanocortin-4 receptor.[4]
3. Central melanocortin system research — Van der Ploeg et al. defined an MC4R role in centrally mediated melanocortin pharmacology; Sweeney, Cone and colleagues reviewed the central melanocortin system in metabolic regulation.[3][6]
4. Preclinical CNS neuroscience — Pfaus and colleagues published rodent studies and a review of central nervous system effects in animal models; Borland et al. reported analyses in a female Syrian hamster model.[8][9][19]
5. Melanocortin neurobiology reviews — Shadiack et al. and Pfaus et al. reviewed the melanocortin literature in this receptor family.[10][11][12]
6. Oncology cell-line research — Suzuki et al. reported that the compound induces cell death and growth inhibition in glioblastoma cells in vitro via suppression of survivin expression, an application entirely separate from the melanocortin neuroscience literature.[18]
7. Cardiovascular pharmacology — White et al. reported the use of ambulatory blood-pressure monitoring to assess this melanocortin receptor agonist.[14]
8. Analytical chemistry and peptide stability — Sauter et al. developed UHPLC-MS/MS quantification of the cyclic peptide; Yuvaraaj and Sharma characterized the acetate salt and its degradants by LC-HRMS/MS with computational modelling of epimerization.[15][16]
9. Forensic and supply-chain analysis — Mestria et al. applied LC-HRMS to characterize melanotan II and bremelanotide material obtained outside regulated supply chains, work directly relevant to material-identity verification.[17]
10. Receptor genetics — Bardhan et al. reviewed melanocortin receptor gene polymorphism and its association with inflammatory traits.[21]
11. Macrocycle design and subtype selectivity — Merlino et al. reported mid-size macrocycle design for selective targeting of human melanocortin receptors.[20]

Comparative Research Context

Within the melanocortin research literature, PT-141 is most directly compared with Melanotan II for the terminal amide-versus-free-acid distinction, and with KPV, an α-MSH fragment that enters cells through the PepT1 transporter rather than engaging melanocortin receptors at all.[2]